Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants
Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants
Background: Despite widespread phototherapy usage, many newborn infants remain in need of
 other lines of invasive therapy such as intravenous immunoglobulins and exchange
 transfusions.

 Objective: To assess the efficacy and the safety of adding fenofibrate to phototherapy for
 treatment of pathological jaundice in full term infants.

 Design/Methods: We conducted a double blinded randomized control study on 180 full-term
 infants with pathological unconjugated hyperbilirubinemia admitted to the NICU of Mansoura
 University Children's Hospital. They were randomly assigned to receive either oral
 fenofibrate 10 mg /kg /day for one day or two days or placebo. Primary outcome was total
 serum bilirubin values after 12, 24, 36, 48 hours from intervention. Secondary outcomes were
 total duration of treatment, need for exchange transfusions and intravenous immunoglobulin,
 exclusive breast-feeding on discharge, and adverse effects of fenofibrate.
Inclusion Criteria:

 -  we included appropriate for gestational age full-term infants with pathological
 unconjugated hyperbilirubinemia who are candidate for phototherapy according to
 American academy of pediatrics guidelines

 Exclusion Criteria:

 -  Full term infants with intrauterine growth restriction, congenital malformations,
 conjugated hyperbilirubinemia, severe jaundice initially required exchange
 transfusion, skin abrasions or infection, and preterm infants were excluded